Enhver patient, som klager over forandringer i den visuelle skarphed eller synsfeltet, eller rapporterer om andre oftalmologiske symptomer under behandling med IntronA, skal straks have foretaget en fuldstændig øjenundersøgelse.
Any patient complaining of changes in visual acuity or visual fields, or reporting other ophthalmologic symptoms during treatment with IntronA, must have a prompt and complete eye examination.